Striking Gold in Orthopedics

01 Jan 2005

• By David Cassak

Orthopedics is a hot space for venture investing right now. But the complexity of the clinical space and the conservative nature of its physicians makes success tricky. Now a group of former orthopedic executives have hit on a new formula for bringing new technologies to market.

It's no secret that over the past several years, orthopedics, and in particular spine, has been one the hottest medical device areas. But the unique nature of ortho/spine, where the clinical issues are complex and diverse and surgeons tend to be conservative technology adopters, makes investment tricky. Now, a group of former orthopedic industry executives believe they've hit on just the right formula, one that rests on bringing management expertise to late-stage technologies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

16 Sep 2024

• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

04 Sep 2024

• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

23 Aug 2024

• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

29 Jul 2024

• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand